Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 14/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.40 |
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10870012 | 0.84 | ITGB3 (0.34) | DPP7ITGB3ITGA2B | |
| SCHEMBL5553779 | 0.80 | DPP4 (0.35) | DPP7DPP8DPP4DPP9FAP | |
| SCHEMBL3277465 | 0.77 | DPP7 (0.45) | DPP7DPP8DPP4DPP9FAP | |
| SCHEMBL11197546 | 0.76 | DPP7 (0.44) | DPP7DPP8DPP4DPP9FAP | |
| SCHEMBL1503226 | 0.75 | CD274 (0.32) | — | |
| SCHEMBL1503225 | 0.75 | CD274 (0.32) | — | |
| SCHEMBL9733790 | 0.74 | CD274 (0.33) | — | |
| SCHEMBL7758752 | 0.72 | DPP7 (0.40) | DPP7DPP8DPP4DPP9FAP | |
| SCHEMBL7318606 | 0.72 | DPP7 (0.43) | DPP7DPP8DPP4DPP9FAP | |
| SCHEMBL10589377 | 0.72 | DPP7 (0.40) | DPP7DPP8DPP4DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | disclosed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1513868-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000874-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | DPP7 312/4885DPP8 356/4885DPP4 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.